ARPA-H awarded up to $125 million under its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program to build a domestic, automated network for producing individualized, on-demand RNA-based genetic medicines. The program targets low-cost production plus quality control testing at or near the point of care. The awards split work across four platform teams and one quality-control systems team. Massachusetts General Hospital will develop a single-use fluidics chip and control hardware for continuous manufacturing and QC, while Centillion Biosciences, HDT Bio, and Waterfall Scientific each lead end-to-end automation architectures for cartridge-based RNA/DNA production and integrated analytical systems. The University of Utah will oversee an all-in-one, same-day testing approach designed for compact lot release.